Global strategies for cervical cancer prevention

Current Opinion in Obstetrics and Gynecology

Volumn 28, Issue 1, 2016, Pages 4-10

  Pimple, Sharmila ^a   Mishra, Gauravi ^a   Shastri, Surendra ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Cervix cancer prevention; Human papillomavirus vaccination; Screening

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST BENEFIT ANALYSIS; EARLY CANCER DIAGNOSIS; ECONOMICS; FEMALE; HEALTH; HEALTH CARE DELIVERY; HEALTH CARE DISPARITY; HUMAN; IMMUNOTHERAPY; INCIDENCE; MASS SCREENING; MOLECULARLY TARGETED THERAPY; PAPILLOMAVIRUS INFECTIONS; PRACTICE GUIDELINE; PROCEDURES; PROTOCOL COMPLIANCE; TRENDS; UTERINE CERVICAL NEOPLASMS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; FEMALE; GLOBAL HEALTH; GUIDELINE ADHERENCE; GUIDELINES AS TOPIC; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; IMMUNOTHERAPY; INCIDENCE; MASS SCREENING; MOLECULAR TARGETED THERAPY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EID: 84952976963     PISSN: 1040872X     EISSN: 1473656X     Source Type: Journal    
DOI: 10.1097/GCO.0000000000000241     Document Type: Review

References (65)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013.
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132:1133- 1145.
3. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65:87-108.
4. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol 2015; 1:505-527.
5. Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007; 370:890-907.
6. IARC. IARC handbooks of cancer prevention. Vol. 10. Cervix cancer screening. Lyon, France: IARC; 2005.
7. Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997; 8:755-763.
8. Arbyn M, Raifu AO, Weiderpass E, et al. Trends of cervical cancer mortality in the member states of the European Union. Eur J Cancer 2009; 45:2640- 2648.
9. Fahey MT, Irwig L, Macaskill P. Meta-analysis of Pap test accuracy. Am J Epidemiol 1995; 141:680-689.
10. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119:1095-1101.
11. Katki HA, Wentzensen N. How might HPV testing be integrated into cervical screening? Lancet Oncol 2012; 13:8-10.
12. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: A systematic review and meta-analysis. Obstet Gynecol 2008; 111:167-177.
13. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer 2008; 123:153-160.
14. Cuzick J, Bergeron C, von Knebel Doeberitz M, et al. New technologies and procedures for cervical cancer screening. Vaccine 2012; 30:F107-F116.
15. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385-1394.
16. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008; 100:492-501.
17. Dijkstra MG, Snijders PJF, Arbyn M, et al. Cervical cancer screening: on the way to a shift from cytology to full molecular screening. Ann Oncol 2014; 25:927-935.
18. Rijkaart DC, Berkhof J, van Kemenade FJ, et al. HPV DNA testing in population- based cervical screening (VUSA-Screen study): results and implications. Br J Cancer 2012; 106:975-981.
19. Kitchener C, Canfell H, Gilham K, et al. Health Technol Assess 2014; 18:1- 196.
20. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009; 101:1612-1623.
21. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007; 370:1764-1772.
22. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: A randomised controlled trial. Lancet Oncol 2010; 11:249- 257.
23. Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012; 30:F88- F99.
24. Sankaranarayanan R, Basu P, Wesley RS, et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer 2004; 110:907-913.
25. Shastri SS, Dinshaw K, Geetanjali A, et al. Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. Bull World Health Organ 2005; 83:186- 194.
26. Wright TC Jr, Kuhn L. Alternative approaches to cervical cancer screening for developing countries. Best Pract Res Clin Obstet Gynaecol 2012; 26:197- 208.
27. Sankaranarayanan R, Esmy PO, Rajkumar R, et al. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: A clusterrandomised trial. Lancet 2007; 370:398-406.
28. Shastri SS, Mittra I, Mishra GA, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst 2014; 106:dju009.
29. Qiao YL, Sellors JW, Eder PS, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: A cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9:929-936.
30. Cuzick J, Cuschieri K, Denton K, et al. Performance of the Xpert HPV assay in women attending for cervical screening. Papillomavirus Res 2015.
31. Nessa A, Hussain MA, Rahman, et al. Screening for cervical neoplasia in Bangladesh using visual inspection with acetic acid. Int J Gynaecol Obstet 2010; 111:115-118.
32. Parham GP, Mwanahamuntu MH, Kapambwe S, et al. Population-level scaleup of cervical cancer prevention services in a low-resource setting: development, implementation, and evaluation of the cervical cancer prevention program in Zambia. PLoS One 2015; 10:e0122169.
33. World Health Organization. WHO guidelines: WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, Switzerland: WHO; 2013.
34. Sankaranarayanan R, Rajkumar R, Esmy PO, et al. Effectiveness, safety and acceptability of 'see and treat' with cryotherapy by nurses in a cervical screening study in India. Br J Cancer 2007; 96:738-743.
35. Castro W, Gage J, Gaffikin L, et al. Effectiveness, safety and acceptability of cryotherapy: A systematic literature review. Cervical cancer prevention issues in depth, No. 1. Seattle, WA: PATH; 2003.
36. Sherris J, Wittet S, Kleine A, et al. Evidence-based, alternative cervical cancer screening approaches in low-resource settings. Int Perspect Sex Reprod Health 2009; 35:147-154.
37. Denny L, Kuhn L, De Souza M, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: A randomized controlled trial. JAMA 2005; 29c4:2173-2181.
38. World Health Organization. Comprehensive cervical cancer control: A guide to essential practice. 2nd ed. Geneva, Switzerland: World Health Organization; 2014.
39. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva, Switzerland: World Health Organization; 2013.
40. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med 2005; 353:2158-2168.
41. Broberg G, Gyrd-Hansen D, Miao Jonasson J, et al. Increasing participation in cervical cancer screening: offering a HPV self-test to long-term nonattendees as part of RACOMIP, a Swedish randomized controlled trial. Int J Cancer 2013; 134:2223-2230.
42. Virtanen A, Nieminen P, Luostarinen T, et al. Self-sample HPV tests as an intervention for nonattendees of cervical cancer screening in Finland: A randomized trial. Cancer Epidemiol Biomarkers Prev 2011; 20:1960-1969.
43. Arbyn M, Verdoodt F, Snijders PJ, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: A meta-analysis. Lancet Oncol 2014; 15:172-183.
44. Verdoodt F, Jentschke M, Hillemanns P, et al. Reaching women who do not participate in the regular cervical cancer screening programme by offering self-sampling kits: A systematic review and meta-analysis of randomised trials. Eur J Caner 2015; 51:2375-2385.
45. Human papillomavirus vaccines: WHO position paper, October 2014. Wkly Epidemiol Rec 2014; 89:465-491.
46. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:89-99.
47. Herrero R, Hildesheim A, Rodríguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008; 26:4795-4808.
48. Romanowski B, Colares de Borba P, Naud PS, et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: Analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009; 374:1975-1985.
49. Naud PS, Roteli-Martins CM, De Carvlho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years postvaccination. Hum Vaccine Immunother 2014; 10:2147-2162.
50. Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by nonvaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012; 13:100-110.
51. Sankarnarayanan R. Screening for cancer in low middle countries. Ann Global Health 2014; 80:412-417.
52. Goldie SJ, O'Shea M, Campos NG, et al. Health and economic outcomes of HPV 16, 18 vaccination in 72 GAVI-eligible countries. Vaccine 2008; 26:4080-4093.
53. World Health Organization. WHO Guidance Note. Comprehensive cervical cancer prevention and control: A healthier future for girls and women. Geneva, Switzerland: WHO; 2013.
54. GAVI Alliance. GAVI funds vaccines to protect girls against cervical cancer [Press Release]. Geneva (CH): GAVI Alliance; 4 February 2013. http://www.gavialliance.org/library/news/press-releases/2013/gavi-funds-vaccinesto-protect-girls-against-cervical-cancer/-.
55. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-1451.
56. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16:775-786.
57. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-2014.
58. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res 2013; 6:1242-1250.
59. Bharati K, Ganguly NK. Does India need an indigenous HPV vaccine and why? J Public Health Policy 2013; 34:272-287.
60. LaMontagne DS, Barge S, Le NT, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011; 89:821-830.
61. Spencer AM, Roberts SA, Brabin L, et al. Sociodemographic factors predicting mother's cervical screening and daughter's HPV vaccination uptake. J Epidemiol Commun Health 2014; 68:571-577.
62. Noronha AS, Markowitz LE, Dunne EF. Systematic review of human papillomavirus vaccine coadministration. Vaccine 2014; 32:2670-2674.
63. Lowy DR, Herrero R, Hildesheim A; Participants in the IARC/NCI workshop on Primary Endpoints for Prophylactic HPV Vaccine Trials. Primary endpoints for future prophylactic human papillomavirus vaccine trials: towards infection and immunobridging. Lancet Oncol 2015; 16:e226-e233.
64. Bosch FX, Broker TR, Forman D, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 2013; 31:11-31.
65. Mallath MK, Taylor DG, Badwe RA, et al. The growing burden of cancer in India: epidemiology and social context. Lancet Oncol 2014; 15:e205- e212.